Iterum Therapeutics plc

Equities

ITRM

IE000TTOOBX0

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:01 2024-04-25 pm EDT			5-day change	1st Jan Change
1.57 ^USD	+1.29%		+9.79%	-20.30%

Mar. 28	Transcript : Iterum Therapeutics plc, Q4 2023 Earnings Call, Mar 28, 2024
Mar. 28	Iterum Therapeutics plc Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	CI

Iterum Therapeutics plc Reports Earnings Results for the First Quarter Ended March 31, 2021

May 14, 2021 at 08:20 am EDT

Iterum Therapeutics plc announced earnings results for the first quarter ended March 31, 2021. For the first quarter, the company announced operating loss was USD 5.847 million compared to USD 12.894 million a year ago. Net loss was USD 98.921 million compared to USD 16.100 million a year ago. Basic loss per share from continuing operations was USD 0.81 compared to USD 1.08 a year ago.

Latest news about Iterum Therapeutics plc

Transcript : Iterum Therapeutics plc, Q4 2023 Earnings Call, Mar 28, 2024	Mar. 28
Iterum Therapeutics plc Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 28	CI
Iterum Therapeutics Plans to Engage Financial Advisor to Evaluate Strategic Alternatives	Mar. 05	CI
HC Wainwright Upgrades Iterum Therapeutics to Buy From Neutral, Price Target is $6	Feb. 07	MT
Transcript : Iterum Therapeutics plc - Special Call	Jan. 30
Iterum Therapeutics Says UTI Drug Trial Met Primary Endpoint	Jan. 30	DJ
Iterum Therapeutics plc Announces Positive Topline Results from Its Phase 3 Reassure Clinical Trial of Oral Sulopenem in Un Complicated Urinary Tract Infections	Jan. 30	CI
Iterum Therapeutics plc Announces the Resignation of Mark Chin as Director, Effective December 31, 2023	Dec. 29	CI
Transcript : Iterum Therapeutics plc, Q3 2023 Earnings Call, Nov 14, 2023	Nov. 14
Iterum Therapeutics plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Iterum Therapeutics plc Announces Completion of Enrollment in its REASSURE Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections	23-10-24	CI
Transcript : Iterum Therapeutics plc, Q2 2023 Earnings Call, Aug 11, 2023	23-08-11
Iterum Therapeutics plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
Iterum Therapeutics plc Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
Transcript : Iterum Therapeutics plc, Q4 2022 Earnings Call, Mar 16, 2023	23-03-16
Transcript : Iterum Therapeutics plc, Q3 2022 Earnings Call, Nov 10, 2022	22-11-10
Iterum Therapeutics plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI
Earnings Flash (ITRM) ITERUM THERAPEUTICS Reports Q3 Loss $-0.43, vs. Street Est of $-0.92	22-11-10	MT
Iterum Therapeutics Reports Dosing First Patient in Late-Stage Urinary Tract Infections Trial	22-10-20	MT
Iterum Announces First Patient Dosed in Reassure, A Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections	22-10-20	CI
Iterum Therapeutics Files $100 Million Mixed-Securities Shelf	22-10-10	MT
Iterum Therapeutics plc Announces Issuance of Allowance for A U.S. Patent Covering Oral Sulopenem	22-09-19	CI
Iterum Therapeutics plc(NasdaqCM:ITRM) dropped from S&P Global BMI Index	22-09-19	CI
Wall Street Futures Tumble Ahead of Fed Minutes	22-08-17	MT
Top Premarket Decliners	22-08-17	MT

Chart Iterum Therapeutics plc

Duration

Period

More charts

Company Profile

Iterum Therapeutics plc is a clinical-stage pharmaceutical company. The Company develops differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. It is advancing its first compound, sulopenem, a novel penem anti-infective compound, in Phase 3 clinical development with an oral formulation. Sulopenem is a potent, thiopenem antibiotic delivered intravenously, which is active against bacteria that belong to the group of organisms known as gram-negatives and causes urinary tract and intra-abdominal infections. It has also developed sulopenem in an oral tablet formulation, sulopenem etzadroxil-probenecid. Sulopenem also has an IV formulation. Sulopenem has demonstrated potent in vitro activity against a variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics.

Sector

Biotechnology & Medical Research

Calendar

2024-05-09 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.57 USD

Average target price

6.5 USD

Spread / Average Target

+314.01%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ITERUM THERAPEUTICS PLC	-20.30%	25.79M
IQVIA HOLDINGS INC.	+1.12%	42.59B
MODERNA, INC.	+6.77%	40.65B
LONZA GROUP AG	+48.09%	40.57B
CELLTRION, INC.	-11.96%	26.77B
ICON PUBLIC LIMITED COMPANY	+6.01%	24.81B
ALNYLAM PHARMACEUTICALS, INC.	-24.92%	18.17B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.63%	11.7B
MEDPACE HOLDINGS, INC.	+27.16%	12.05B
UNITED THERAPEUTICS CORPORATION	+7.30%	11.1B

Other Biotechnology & Medical Research